SPORE for Translational Approaches to Brain Cancer

概述：总结 西北脑肿瘤孢子的总体目标是改善脑肿瘤的预后 患者关于脑肿瘤发病率的统计数据表明，超过23，000人将被诊断患有脑肿瘤。 2017年，美国将有大约17，000人死于脑瘤。各种主要的 在脑内肿瘤中，胶质母细胞瘤（GBM）是最常见的。接受标准治疗的GBM患者 治疗的中位生存期为15个月，5年生存期极为罕见。的成就 对这种致命肿瘤的更好治疗一直令人失望。这种缺乏治疗的主要原因是 改善是发生这种癌症的器官的微妙性质。有很大的限制， 如何积极GBM患者可以手术治疗，以及全身给药的疗效 由于进入大脑的途径有限，治疗常常受到损害。为了解决公共卫生问题， 与胶质母细胞瘤有关，我们已经组建了一个有才华的研究团队， 脑肿瘤研究和治疗的背景。这个团队的所有成员都有专业记录 这表明他们在指导自己的研究项目方面取得了成功。大约3年多前，这些教师发起了 小组互动，以使团队科学的方法承担对GBM的研究和治疗， 为此需要采取多学科办法，以取得有意义的进展。

OVERVIEW: SUMMARY The overall objective of the Northwestern Brain Tumor SPORE is to improve outcomes for brain tumor patients. Statistics on brain tumor incidence indicate that more than 23,000 people will be diagnosed with a brain tumor in the U.S. in 2017, and approximately 17,000 will succumb to their disease. Of the various primary intracerebral neoplasms, glioblastoma (GBM) is the most common. GBM patients that receive standard-of-care treatment have a median survival of 15 months, and 5-year survival is extremely rare. Progress in developing better treatments for this lethal tumor has been disappointing. A major contributor to this lack of therapeutic improvement is the delicate nature of the organ in which this cancer occurs. There are significant limitations to how aggressively GBM patients can be treated surgically, and the efficacy of systemically administered therapies are often compromised due to limited access to the brain. To address the public health problem that is associated with glioblastoma, we have assembled a talented team of investigators with extensive backgrounds in brain tumor research and therapy. All members of this team have professional records indicating success in directing their own programs of research. Some 3+ years ago, these faculty initiated group interactions in order to bring a team science approach to bear upon the study and treatment of GBM, and for which a multidisciplinary approach is needed for achieving meaningful progress.